# Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane

> **NCT00936026** · PHASE1 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH**

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Neramexane

## Key facts

- **NCT ID:** NCT00936026
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** — (—)
- **Last updated:** 2011-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00936026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00936026, "Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00936026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*